Characteristic Fetal Brain MRI Abnormalities in Pyruvate Dehydrogenase Complex Deficiency

Olivier Fortin, Kelsey Christoffel, Abdullah Shoaib, Charu Venkatesan, Kate Cilli, Jason W. Schroeder, Cesar Alves, Rebecca D. Ganetzky, Jamie L. Fraser
doi: https://doi.org/10.1101/2024.04.08.24303574

Abstract

Pyruvate dehydrogenase complex deficiency (PDCD) is a disorder of mitochondrial metabolism that is caused by pathogenic variants in multiple genes, including PDHA1. Typical neonatal brain imaging findings in PDCD have been described, with a focus on malformative features and chronic encephaloclastic changes. However, fetal brain MRI imaging in confirmed PDCD has not been comprehensively described. We sought to demonstrate the prenatal neurological and systemic manifestations of PDCD determined by comprehensive fetal imaging and genomic sequencing.

All fetuses with a diagnosis of genetic PDCD who had undergone fetal MRI were included in the study. Medical records, imaging data, and genetic testing results were reviewed and reported descriptively.

Ten patients with diagnosis of PDCD were included. Most patients had corpus callosum dysgenesis, abnormal gyration pattern, reduced brain volumes, and periventricular cystic lesions. One patient had associated intraventricular hemorrhages. One patient had a midbrain malformation with aqueductal stenosis and severe hydrocephalus. Fetuses imaged in the second trimester were found to have enlargement of the ganglionic eminences with cystic cavitations, while those imaged in the third trimester had germinolytic cysts.

Fetuses with PDCD have similar brain MRI findings to neonates described in the literature, although some of these findings may be subtle early in pregnancy. Additional features, such as cystic cavitations of the ganglionic eminences, are noted in the second trimester in fetuses with PDCD, and these may represent a novel early diagnostic marker for PDCD. Using fetal MRI to identify these radiological hallmarks to inform prenatal diagnosis of PDCD may guide genetic counseling, pregnancy decision-making, and neonatal care planning.

Introduction

Pyruvate dehydrogenase complex (PDC) deficiency (PDCD) is an inborn error of metabolism caused by pathogenic variants in various genes related to the PDC, a multiple enzyme complex that plays a critical role in mitochondrial energy production.1–3 Pyruvate, a product of glycolysis, is normally converted by the PDC into acetyl-CoA, which then enters the citric acid cycle to produce ATP. When PDC cannot convert pyruvate to acetyl co-A, the excess pyruvate is converted into lactate, causing lactic acidosis and energy failure that are often initial signs of PDCD. For this reason, the ketogenic diet is often used to bypass carbohydrate metabolism and the subsequent energy failure (Figure 1).1,3–5

Figure 1:
Figure 1: Schematic representation of the PDC and related enzymatic pathways.

Thiamine pyrophosphate is the requisite cofactor for the PDC as well as branched chain amino acid catabolism and tricarboxylic acid cycle function. Ketogenic diet bypasses the PDCD complex while enabling ATP synthesis through fatty acid oxidation. ATP: adenosine triphosphate; B1: vitamin B1; ECHS1: short-chain enoyl-CoA hydratase; HIBCH: beta-hydroxyisobutyryl-CoA hydrolase; PDC: pyruvate dehydrogenase complex; OGDH: oxoglutarate dehydrogenase; TCA: tricarboxylic acid; TPK: thiamine pyrophosphokinase; TPP: thiamine pyrophosphate. Created with BioRender.com.

The most common pathogenic variants associated with PDCD occur in PDHA1 which encodes the alpha subunit of the pyruvate dehydrogenase enzyme (a component of the E1 subenzyme of the PDC).1,3,6 Inheritance for this gene is X-linked, but both males and females have been described with PDHA1 pathogenic variants. Neonates with the severe neurologic disease are usually female.7 Rare variants (all with autosomal recessive inheritance) have also been identified in genes coding other components of the PDC, including PDHB, DLAT, DLD, PDHX, and the regulatory enzyme PDP1.1,3 PDCD also occurs secondary to conditions that impair PDC function, such as dietary thiamine deficiency and enzyme dysfunction upstream in the biochemical pathway that lead to deficiencies in cofactors necessary for PDC function.3 Examples of such genetic disorders include Thiamine pyrophosphokinase deficiency (related to biallelic pathogenic variants in TPK1), Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency (related to biallelic pathogenic variants in ECHS1), and 3-hydroxyisobutyryl-CoA hydrolase deficiency (related to biallelic pathogenic variants in HIBCH).

Multiple phenotypes of PDCD occur with onset in neonates, infants, children, and even adults.1,8,9 The metabolic phenotype of encephalopathy, lactic acidosis, hypotonia, and seizures commonly present in neonates with PDCD with or without central nervous system malformations.3,10,11 Craniofacial abnormalities are common, including microcephaly, frontal bossing, low-set ears, upturned nose, long flat philtrum, and thin upper lips.1,3 Although there is no curative treatment for PDCD, ketogenic diet and thiamine supplementation have been described to improve neurological outcomes in mild to moderate cases.3,10 Severe cases may show little benefit from treatment, and there is significant risk of death in the first few months of life. Typical brain MRI findings of neuronopathic PDCD have been documented in infants and children. These include chronic encephaloclastic changes – periventricular white matter cavitations, diffuse parenchymal atrophy, and ventriculomegaly – as well as corpus callosum dysgenesis and brainstem malformations.1,3,6,10,12 A lactate peak on MR spectroscopy (MRS) has also been described in neonates with PDCD.5,13,14 Children with PDCD may also present later in life with Leigh-like changes on brain MRI, including T2-weighted changes and diffusion restriction involving the basal ganglia – with particular predilection for the globus pallidus – as well as the thalamus and brainstem.10,12,15 Congenital brain malformations may not be present in childhood-onset PDCD.

Imaging findings of PDCD in the prenatal period are less well described, with few case reports and series of brain abnormalities identified prenatally, either on fetal ultrasound or MRI. Imaging findings of neuronopathic PDCD in the prenatal period may include corpus callosum dysgenesis, cortical gyration abnormalities, ventriculomegaly, reduced white matter volumes, as well as reduced brainstem and cerebellar volumes.6,13,16–20 One series reported fetal MRI findings for 3 fetuses who were diagnosed with PDCD, one with pathogenic variants in PDHA1 and two (siblings) with pathogenic variants in PDHB.6 Fetal MRS, although currently limited in its clinical application,21–23 was reported to be normal in a fetus with suspected PDCD (based on family history and clinical course but not confirmed with genetic testing), with no lactate peak.16

Given the paucity of data on fetal imaging and diagnosis in this rare disorder, we sought to report cases of PDCD identified through fetal diagnostic clinics in pediatric hospital centers in the United States.

Materials and Methods

Retrospective medical records review was performed to identify fetuses and neonates with a genetic diagnosis of PDCD who underwent fetal imaging by MRI between January 1, 2010, and October 17, 2023 in the fetal diagnostic clinics at the authors’ institutions. All authors obtained either IRB approval or IRB exemption from their respective centers. Waiver of consent was granted based on the retrospective nature of the study.

Available medical records, imaging studies, and genetic testing of the fetus and mother were reviewed. Postnatal medical records were reviewed, if available. Pregnancy history, maternal medical history, family history, imaging features, genetic testing results, and clinical outcomes were analyzed and reported in a descriptive fashion. To further de-identify these cases, at the direction of the journal’s editorial office, the gestational ages (GA) of all cases are indicated within two-week GA ranges throughout.

Fetal MRI imaging for the cohort was overread by fetal and pediatric neuroradiologist J.W.S. for descriptive and technical consistency. Fetal imaging at Children’s National Hospital was performed on a 1.5 Tesla scanner (GE HealthCare, Chicago, Illinois; Siemens Healthineers, Erlangen, Germany); unenhanced fast T1-weighted, T2-weighted, and diffusion-weighted images were generated in various planes based on the local fetal imaging protocol. Imaging at Cincinnati Children’s Hospital Medical Center was performed on a 1.5 Tesla scanner (GE HealthCare, Chicago, Illinois; Philips Healthcare, Best, Netherlands). Imaging at Children’s Hospital of Philadelphia was performed on a 1.5 Tesla scanner (Siemens Healthineers, Erlangen, Germany). Imaging performed at University of Texas Southwestern was performed on a 1.5 Tesla scanner (Siemens Healthineers, Erlangen, Germany).

Neonatal imaging at Children’s National Hospital was performed on a 1.5 Tesla scanner (GE HealthCare, Chicago, Illinois). Unenhanced fast T1-weighted, T2-weighted, diffusion-weighted, and susceptibility-weighted images were generated in orthogonal planes based on the local neonatal imaging protocol; when done, MR spectroscopy was obtained using single voxel long and short TE through the left basal ganglia. Imaging at Cincinnati Children’s Hospital Medical Center was performed on a 1.5 Tesla or 3 Tesla scanner (GE HealthCare, Chicago, Illinois; Philips Healthcare, Best, Netherlands). Imaging at Children’s Hospital of Philadelphia was performed on a 1.5 Tesla scanner (Siemens Healthineers, Erlangen, Germany). Imaging at University of Texas Southwestern was performed on a 1.5 Tesla scanner (Siemens Healthineers, Erlangen, Germany).

Genetic testing strategies varied at the discretion of the treating providers at the time of the clinical evaluation and included single-gene testing, multi-gene panels, and exome sequencing (ES). Hospital laboratories or commercial laboratories (MNG Laboratories, Atlanta, Georgia; GeneDx, Gaithersburg, Maryland; Claritas Genomics, Cambridge, Massachusetts) were used based on patient insurance coverage, institutional policies, and availability of testing in the respective centers. Genetic variant pathogenicity was reported by clinical genetics laboratories using recognized ACMG criteria; they were individually evaluated for confirmation and or diagnostic validity by three of the authors (O.F., R.D.G., J.L.F.).

Results

Demographics

Ten cases of diagnosed PDCD who underwent fetal MRI in fetal diagnostic clinics at the authors’ institutions were included. All cases were genetically confirmed to be female. Six cases were evaluated between 20w and 29w gestational age (GA), whereas 4 fetuses were evaluated between 30w and 35w GA (Table 1).

View this table:
Table 1: Genetic variants, fetal MRI findings, and outcomes in reported patients with PDCD

Fetal Imaging

Fetal MRI findings are detailed in Table 1 and Figure 2. Eight fetuses had abnormalities of corpus callosum (either ACC or dysplastic CC), all cases had parenchymal volume loss, 7 cases had varying degrees of ventriculomegaly, 5 cases had cerebellar hypoplasia, and 6 cases had some form of cortical malformation (either delayed sulcation or frank polymicrogyria). Nine cases had cystic changes: those imaged in the second trimester or early third trimester (n=6) had cystic cavitations in one or both ganglionic eminences (GE), whereas those imaged later in the pregnancy (n=3) had periventricular or germinolytic cysts. One fetus imaged between 28 weeks and 30 weeks GA (Case 7) had a midbrain malformation with aqueductal stenosis that resulted in severe and progressive ventriculomegaly; cystic changes were not seen in this fetus. Figure 3 and 4 show examples of fetal and neonatal brain imaging.

Figure 2:
Figure 2: Fetal MRI Findings in Fetuses with PDCD

Most fetal cases had multiple brain anomalies or malformations at the time of fetal MRI (N=10). CBLH: cerebellar hypoplasia; CCD: corpus callosum dysgenesis; GE: ganglionic eminence; MCD: malformation of cortical development; PV: periventricular; VM: ventriculomegaly

Figure 3:
Figure 3: Fetal and postnatal brain MRI/MRS findings in PDCD (Case 1)

Imaging findings from Case 1 include the first prenatal imaging (20-22w GA; A-D), the second prenatal imaging (24-26w GA; E-H), and neonatal imaging with magnetic resonance spectroscopy (I-L). A-D: T2-weighted fetal MRI in the axial (A), coronal (B, C), and sagittal (D) planes, showing ganglionic eminence cystic cavitations (while arrowheads; A, B, D), ventriculomegaly (white arrowhead; C), and corpus callosum dysgenesis. E-H: T2-weighted fetal MRI at in the axial (E), coronal (F-G), and sagittal (H) planes, showing progression of ganglionic eminence changes (arrowheads; E, F, H) and ventriculomegaly (arrowheads; G), as well as corpus callosum dysgenesis. I-L: T2 weighted (I, J, K) and T1-weighted (L) neonatal brain MRI in the axial (I), coronal (J, K), and sagittal (L) planes, showing basal ganglia abnormalities with surrounding cysts (arrowheads; I, J, L), progression of ventriculomegaly (arrowheads; K), volume loss, and corpus callosum dysgenesis. M: Neonatal brain MRS showing elevated lactate peak (arrow).

Figure 4:
Figure 4: Fetal and postnatal brain MRI findings in select cases of PDCD

A-D: T2-weighted fetal MRI (20-22w GA) in the axial (A, B), coronal (C), and sagittal (D) planes in a fetus with PDHA1-related PDCD (Case 5), showing ganglionic eminence cystic cavitations (arrowheads; A, B, C, D) and corpus callosum dysgenesis. E-H: T2-weighted fetal MRI (22-24w GA) in the axial (E), coronal (F), and sagittal (G-H) planes in a patient with TPK1-related disorder (Case 10), showing ganglionic eminence cystic cavitations (arrowheads; E, F, G, H) and corpus callosum dysgenesis. I-L: T2 weighted fetal MRI at (24-26w GA) in the axial (I, J), coronal (K), and sagittal (L) planes in a patient with PDHA1-related PDCD (Case 2), showing periventricular cysts (arrowheads; I, J, K, L). M-P: T2-weighted postnatal brain MRI in the axial (M), coronal (N), and sagittal (O-P) planes in a patient with PDHA1-related PDCD (Case 2), showing progression of the periventricular cysts (arrowheads; M, N, O) and hypoplastic corpus callosum (arrowhead; P).

Genetic Diagnoses

Three patients underwent amniocentesis for genetic testing by ES; all results were obtained postnatally or after termination. Two patients underwent genetic testing from products of conception. Five patients underwent genetic testing in the postnatal period.

Nine cases were eventually found to have heterozygous pathogenic or likely pathogenic variants in PDHA1, consistent with a primary PDCD deficiency (Table 1). One case was found to have biallelic (compound heterozygous) likely pathogenic variants in TPK1.

Pregnancy Outcomes

Termination of pregnancy occurred in 4 cases based on the poor neurological prognosis. The remaining cases (n=6) were delivered at term, except for 1 who was delivered late preterm (between 34 weeks and 36 weeks GA). Neonatal management and postnatal outcomes are detailed in Table 2. Two infants expired in the neonatal intensive care unit (Cases 1 and 7). Ketogenic diet was started during the neonatal period in Cases 3 and 6. Case 9 was started on ketogenic diet in infancy for infantile spasms. For Case 2, ketogenic diet was recommended but not started by the family. Five patients underwent follow-up brain MRI in the neonatal period (Table 2). Three neonates also underwent brain MRS.

View this table:
Table 2: Postnatal Management and Outcomes

Discussion

We present ten cases of PDCD evaluated in comprehensive prenatal diagnosis programs for abnormal fetal brain findings and later found to have pathogenic variants in genes either within the PDC or in upstream or adjacent enzymatic pathways: nine had de novo heterozygous likely pathogenic or pathogenic variants PDHA1 and one had biallelic likely pathogenic variants in TPK1. Although the brain imaging findings of neonatally-identified PDCD are likely related to prenatal onset of the disease, fetal neuroimaging descriptions are less well described with a lack of correlation with the postnatal features. In this study, we demonstrate the progression of brain malformations from the prenatal to the postnatal period and report on abnormalities previously underappreciated in PDCD.

Although PDHA1-related disorder is a recognized cause of congenital brain malformations,1,10,12 significant brain malformations have never been reported with TPK1 disease-causing variants. TPK1 encodes for the enzyme thiamine pyrophosphokinase, which synthesizes thiamine pyrophosphate (TPP), an essential cofactor for PDC function. TPK1-related disorder usually presents in childhood with variable severity of ataxia, dystonia, spasticity, developmental delay, encephalopathy, and hypotonia; these children may also have episodes of neurological decompensation and developmental regression after febrile illness with brain MRI changes reminiscent of Leigh disease.24–28 Supraphysiological supplementation of thiamine with or without ketogenic diet has been reported to salvage the metabolic encephalopathic phenotype and improve developmental outcomes.24–28 The patient with the youngest reported onset of symptoms in the literature was 1 month of age when she started to have seizures, although the neurological deterioration only presented later in early childhood.28 Fetal onset of neurological concerns in TPK1-related disorder has not been described in the literature, although a neonatal case reported by two co-authors is forthcoming. The case reported in this study would be the first fetal case of TPK1-related disorder. Thus, TPK deficiency may be an underrecognized cause of congenital brain malformations. TPK is highly intolerant to variation in humans, as biallelic loss of function variants have not been observed in humans. Severe TPK deficiency may lead to embryonic lethality, while moderate deficiency may be sufficient to cause the characteristic features of PDCD on fetal MRI. All genes encoding enzymes in the PDC pathway should be evaluated in cases of fetal brain malformations reported herein.

Some of the features on fetal MRI in our patients overlap with the neonatal findings described in the literature,1,10,12 including corpus callosum dysgenesis, abnormal gyration pattern, and reduced volumes of the supratentorial and infratentorial compartments of the brain with periventricular cystic cavitations. A brainstem malformation was noted in one patient, resulting in aqueductal stenosis and severe obstructive hydrocephalus, making the diagnosis of a metabolic disorder such as PDCD appear unlikely until an extensive genetic evaluation was performed after birth. One patient had bilateral intraventricular hemorrhages, which also may steer clinicians away from investigating a genetic disorder such as PDCD.

When comparing with the available literature on fetal brain MRI findings in PDCD,6,13,14,16–20 we noted that the majority of our cases (90%) had cystic changes, whereas this is reported to be present in about 50% of cases in a recent review.20 Cystic changes were not seen in one fetus (Case 7) but these may have been effaced by the severe hydrocephalus. Non-hemorrhagic caudothalamic groove cysts, or germinolytic cysts, were seen in fetuses that were imaged in the third trimester. The other fetuses that were imaged in the second trimester or early third trimester had more prominent cystic cavitations in one or both ganglionic eminences (GE), usually associated with enlargement of these structures. Upon review of the available fetal MRIs of two patients with PDHA1- and PDHB-related PDCD, reported by Pirot et al.6, their imaging between 26 weeks and 28 weeks GA also appears to show cystic cavitations within the GEs, although these were described as “paraventricular pseudocysts” at the time.

GEs are a normal fetal structure within the telencephalon that naturally evolve during central nervous system (CNS) development, later giving rise to the basal ganglia.29–31 Based on recent reports of volumetric measurements from quantitative fetal MRI, they appear to increase in size throughout the first and second trimester, then involute in the late second trimester and third trimester.32 The GE is divided between medial, lateral, and caudal segments (MGE, LGE, and CGE, respectively), and each segment is thought to contain specific progenitor cells that give rise to various interneurons essential to brain function.30,33 For example, cells in the MGE produce GABAergic neurons that project to the striatum and globus pallidus as well as interneurons that migrate tangentially to the cerebral cortex, whereas cells in the CGE produce GABAergic interneurons that project to the limbic system, and cells in the LGE produce interneurons destined for to the olfactory bulb, amongst others.30 Complex gene and protein functions control the proliferation, differentiation, and migration of cells arising from GE subsegments.30 The GE, as well as pathology involving these structures, may be visualized by fetal ultrasound and MRI.34–37 GE cystic cavitations are a rare finding on fetal brain MRI and were first reported in 2013. These findings were initially linked to microlissencephalies related to LIS1 or TUBA1A pathogenic variants.37,38 A larger study of 22 fetuses with GE abnormalities, including cystic cavitations, using ES found that this specific malformation was associated with pathogenic variants in TUBA1A in 7 patients and PDHA1 in one patient.39 The fetus with PDCD described by Goergen et al.39 was imaged between 22 weeks and 24 weeks GA and also had ACC. GE cystic cavitations have not been seen with TPK1-related disorder in the literature. Combined with our work, this suggests that cystic cavitations of the GE could be an early diagnostic marker of PDCD on second trimester fetal MRI, especially when associated with corpus callosum dysgenesis; this finding appears to “convert” to the more typical caudothalamic groove or germinolytic cyst in the third trimester. The exact pathophysiological link between PDCD and GE cystic cavitations is unclear. Germinal matrix hemorrhage in premature infants has been shown to alter cell proliferation in the GE via different pathways including inflammation and necrosis29; an analogous process may be at play in PDCD, whereby mitochondrial dysfunction and energy failure in this highly proliferative and metabolically demanding structure leads to cell death and subsequent structural changes. Evidence of hemorrhage may be secondary to rapid cell death and involution in this region and not a primary cause of tissue injury. The timing and locations of severe metabolic injury in the fetuses described herein point to the significant energy demand of these developing structures, which is not met in PDCD. The evolution of fetal mitochondrial brain injury in PDCD correlates with observed and expected injury of the most metabolically demanding brain structures postnatally. Thus, mitochondrial dysfunction from PDCD that manifests in the prenatal period disrupts cortical developmental patterning, decreases cerebral volume, and causes tissue destruction of the GE, findings that can be seen on fetal MRI in the second trimester.

Given that the fetal radiological features of PDHA1- and TPK1-related disorders may mimic destructive and malformation disorders of the CNS, we suggest that all genes causing PDCD be included in the differential diagnosis of many fetal brain disorders, especially with corpus callosum dysgenesis, cortical migration disorders, and periventricular cystic changes in combination. Even in cases with apparently isolated abnormalities of the corpus callosum, one should consider an underlying genetic disorder such as PDCD, given that some of the other changes may not be detected on fetal MRI. Up to 25% of cases with fetal diagnosis of isolated corpus callosum dysgenesis may eventually have a postnatal diagnosis of complex corpus callosum anomaly (i.e. associated with other brain malformations).40,41 The yield of expanded genetic testing in isolated and complex agenesis of the corpus callosum is not well known, given that most larger studies have used chromosome microarray (CMA) only; yield of copy number and chromosome-based testing has been reported to be between 5% and 7%.42–44 One study reported that 16% of patients with isolated ACC and 26% of patients with complex ACC obtained a genetic diagnosis in the postnatal period, although the testing regimen is not described in detail or standardized.40 Given the myriad monogenetic disorders associated with both isolated and complex ACC,45 including PDCD, CMA alone is insufficient in most cases. Large gene panels that include PDHA1 or ES would be necessary to identify these etiologies. The use of ES in prenatal testing for fetal diagnosis has shown use in various neurological and non-neurological fetal phenotypes,46 although the yield of systematic sequencing-based testing in fetal diagnosis of ACC is unknown. Given that significant and potentially actionable diagnoses, such as PDCD, that can present with ACC only few other fetal MRI findings – especially early on in fetal brain development, it is essential to offer ES in addition to CMA, although this may depend on local regulatory, insurance, and financial contexts.

While postnatal MRS has been used to support a diagnosis of PDCD and other mitochondrial disorders, fetal MRS is not routinely used. Literature supporting the utility and validity of MRS in the fetal population has recently advanced this concept as a viable modality in prenatal imaging.21–23 In cases where mitochondrial disease is suspected based on fetal imaging phenotypes, MRS may provide additional confirmatory evidence of disease and clarify prognosis for families. Advanced fetal imaging, including MRI with volumetric studies and MRS, may be a useful adjunct for prognosis discussions and counselling while genetic testing is pending.

We thus present ten cases of primary or secondary PDCD that were evaluated prenatally with fetal MRI. All cases showed typical MRI findings of PDCD, including corpus callosum dysgenesis, abnormal gyration pattern, and periventricular cystic lesions, although these were at times subtle on fetal imaging. Ganglionic eminence enlargement with cystic cavitation may represent an early diagnostic marker for severe PDCD on second trimester fetal MRI, although disorders such as tubulinopathies must also be considered in the differential diagnosis and genetic testing approach. Fetuses with PDCD may also present with brain malformations that are not typically consistent with this metabolic disorder, such as aqueductal stenosis and hydrocephalus. Genetic testing must include genes related to PDCD in all cases of corpus callosum dysgenesis, cortical malformation, or cystic changes of the brain. We recommend clinical genome sequencing or exome sequencing in combination with chromosomal microarray as the optimal diagnostic approach in these cases to detect both copy number and single nucleotide variants over gene panels or microarray alone. Timely identification of characteristic imaging features of PDCD is necessary to expedite genetic testing and earlier diagnosis, which in turn may impact pregnancy planning and postnatal outcomes.

Data availability

De-identified data will be made available upon reasonable request to the corresponding author.

Funding

This project relied on institutional salary support for the authors. Dr. Christoffel receives research support for unrelated endeavors from T32HD098066. Dr. Fraser receives research support for unrelated endeavors from U01NS106845-01A1, U54NS115052-01, and U24NS131172-01in addition to philanthropic support from grateful families and generous donors.

Competing interests

The authors report no competing interests

Acknowledgements

We would like to thank our patients and their families for their essential contributions to this work. We would also like to thank all staff and providers that have provided care and expertise to the patients and their families at our respective institutions.

References

  1. 1.↵
    Barnerias C, Saudubray JM, Touati G, et al. Pyruvate dehydrogenase complex deficiency: four neurological phenotypes with differing pathogenesis. Dev Med Child Neurol. 2010;52(2):e1–e9. doi:10.1111/j.1469-8749.2009.03541.x
    OpenUrlCrossRefPubMed
  2. 2.
    Illsinger S, Das AM. Impact of selected inborn errors of metabolism on prenatal and neonatal development. IUBMB Life. 2010;62(6):403–413. doi:10.1002/iub.336
    OpenUrlCrossRefPubMed
  3. 3.↵
    Ganetzky R, McCormick EM, Falk MJ. Primary Pyruvate Dehydrogenase Complex Deficiency Overview. In: Adam MP, Everman DB, Mirzaa GM, et al., eds. GeneReviews®. University of Washington, Seattle; 1993. Accessed September 29, 2022. http://www.ncbi.nlm.nih.gov/books/NBK571223/
  4. 4.
    Brown GK, Otero LJ, LeGris M, Brown RM. Pyruvate dehydrogenase deficiency. J Med Genet. 1994;31(11):875–879.
    OpenUrlFREE Full Text
  5. 5.↵
    Robinson BH, MacMillan H, Petrova-Benedict R, Sherwood WG. Variable clinical presentation in patients with defective E1 component of pyruvate dehydrogenase complex. J Pediatr. 1987;111(4):525–533. doi:10.1016/S0022-3476(87)80112-9
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Pirot N, Crahes M, Adle-Biassette H, et al. Phenotypic and Neuropathological Characterization of Fetal Pyruvate Dehydrogenase Deficiency. J Neuropathol Exp Neurol. 2016;75(3):227–238. doi:10.1093/jnen/nlv022
    OpenUrlCrossRefPubMed
  7. 7.↵
    Ah Mew N, Loewenstein JB, Kadom N, et al. MRI Features of 4 Female Patients With Pyruvate Dehydrogenase E1 alpha Deficiency. Pediatr Neurol. 2011;45(1):57–59. doi:10.1016/j.pediatrneurol.2011.02.003
    OpenUrlCrossRefPubMed
  8. 8.↵
    Prasad C, Rupar T, Prasad AN. Pyruvate dehydrogenase deficiency and epilepsy. Brain Dev. 2011;33(10):856–865. doi:10.1016/j.braindev.2011.08.003
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Cross JH, Connelly A, Gadian DG, et al. Clinical diversity of pyruvate dehydrogenase deficiency. Pediatr Neurol. 1994;10(4):276–283. doi:10.1016/0887-8994(94)90122-8
    OpenUrlCrossRefPubMed
  10. 10.↵
    Patel KP, O’Brien TW, Subramony SH, Shuster J, Stacpoole PW. The spectrum of pyruvate dehydrogenase complex deficiency: Clinical, biochemical and genetic features in 371 patients. Mol Genet Metab. 2012;106(3):385–394. doi:10.1016/j.ymgme.2012.03.017
    OpenUrlCrossRefPubMed
  11. 11.↵
    Soares-Fernandes JP, Teixeira-Gomes R, Cruz R, et al. Neonatal pyruvate dehydrogenase deficiency due to a R302H mutation in the PDHA1 gene: MRI findings. Pediatr Radiol. 2008;38(5):559–562. doi:10.1007/s00247-007-0721-9
    OpenUrlCrossRefPubMed
  12. 12.↵
    Savvidou A, Ivarsson L, Naess K, et al. Novel imaging findings in pyruvate dehydrogenase complex (PDHc) deficiency—Results from a nationwide population-based study. J Inherit Metab Dis. 2022;45(2):248–263. doi:10.1002/jimd.12463
    OpenUrlCrossRef
  13. 13.↵
    Rahesh J, Anand R, Mendiola V, Jacob R. Pyruvate dehydrogenase complex deficiency mimicking congenital cytomegalovirus infection on imaging. Bayl Univ Med Cent Proc. 2022;35(2):232–233. doi:10.1080/08998280.2021.1999192
    OpenUrlCrossRef
  14. 14.↵
    Zand DJ, Simon EM, Pulitzer SB, et al. In Vivo Pyruvate Detected by MR Spectroscopy in Neonatal Pyruvate Dehydrogenase Deficiency. Am J Neuroradiol. 2003;24(7):1471–1474.
    OpenUrlPubMedWeb of Science
  15. 15.↵
    Alves CAPF, Teixeira SR, Martin-Saavedra JS, et al. Pediatric Leigh Syndrome: Neuroimaging Features and Genetic Correlations. Ann Neurol. 2020;88(2):218–232. doi:10.1002/ana.25789
    OpenUrlCrossRefPubMed
  16. 16.↵
    Robinson JN, Norwitz ER, Mulkern R, Brown SA, Rybicki F, Tempany CMC. Prenatal diagnosis of pyruvate dehydrogenase deficiency using magnetic resonance imaging. Prenat Diagn. 2001;21(12):1053–1056. doi:10.1002/pd.187
    OpenUrlCrossRefPubMed
  17. 17.
    Natarajan N, Tully HM, Chapman T. Prenatal presentation of pyruvate dehydrogenase complex deficiency. Pediatr Radiol. 2016;46(9):1354–1357. doi:10.1007/s00247-016-3585-z
    OpenUrlCrossRef
  18. 18.
    Tamaru S, Kikuchi A, Takagi K, et al. A case of pyruvate dehydrogenase E1α subunit deficiency with antenatal brain dysgenesis demonstrated by prenatal sonography and magnetic resonance imaging. J Clin Ultrasound. 2012;40(4):234–238. doi:10.1002/jcu.20864
    OpenUrlCrossRefPubMed
  19. 19.
    Wada N, Matsuishi T, Nonaka M, Naito E, Yoshino M. Pyruvate dehydrogenase E1α subunit deficiency in a female patient: evidence of antenatal origin of brain damage and possible etiology of infantile spasms. Brain Dev. 2004;26(1):57–60. doi:10.1016/S0387-7604(03)00072-X
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    Egloff C, Eldin de Pecoulas A, Mechler C, et al. Prenatal sonographic description of fetuses affected by pyruvate dehydrogenase or pyruvate carboxylase deficiency. Prenat Diagn. 2018;38(8):607–616. doi:10.1002/pd.5282
    OpenUrlCrossRef
  21. 21.↵
    Evangelou IE, Plessis AJ du, Vezina G, Noeske R, Limperopoulos C. Elucidating Metabolic Maturation in the Healthy Fetal Brain Using 1H-MR Spectroscopy. Am J Neuroradiol. 2016;37(2):360–366. doi:10.3174/ajnr.A4512
    OpenUrlAbstract/FREE Full Text
  22. 22.
    Pradhan S, Kapse K, Jacobs M, et al. Non-invasive measurement of biochemical profiles in the healthy fetal brain. NeuroImage. 2020;219:117016. doi:10.1016/j.neuroimage.2020.117016
    OpenUrlCrossRef
  23. 23.↵
    Limperopoulos C, Tworetzky W, McElhinney DB, et al. Brain Volume and Metabolism in Fetuses With Congenital Heart Disease. Circulation. 2010;121(1):26–33. doi:10.1161/CIRCULATIONAHA.109.865568
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    Fraser JL, Vanderver A, Yang S, et al. Thiamine pyrophosphokinase deficiency causes a Leigh Disease like phenotype in a sibling pair: identification through whole exome sequencing and management strategies. Mol Genet Metab Rep. 2014;1:66–70. doi:10.1016/j.ymgmr.2013.12.007
    OpenUrlCrossRef
  25. 25.
    Marcé-Grau A, Martí-Sánchez L, Baide-Mairena H, Ortigoza-Escobar JD, Pérez-Dueñas B. Genetic defects of thiamine transport and metabolism: A review of clinical phenotypes, genetics, and functional studies. J Inherit Metab Dis. 2019;42(4):581–597. doi:10.1002/jimd.12125
    OpenUrlCrossRef
  26. 26.
    Mayr JA, Freisinger P, Schlachter K, et al. Thiamine Pyrophosphokinase Deficiency in Encephalopathic Children with Defects in the Pyruvate Oxidation Pathway. Am J Hum Genet. 2011;89(6):806–812. doi:10.1016/j.ajhg.2011.11.007
    OpenUrlCrossRefPubMed
  27. 27.
    Banka S, de Goede C, Yue WW, et al. Expanding the clinical and molecular spectrum of thiamine pyrophosphokinase deficiency: A treatable neurological disorder caused by TPK1 mutations. Mol Genet Metab. 2014;113(4):301–306. doi:10.1016/j.ymgme.2014.09.010
    OpenUrlCrossRefPubMed
  28. 28.↵
    Huang W, Qin J, Liu D, et al. Reduced thiamine binding is a novel mechanism for TPK deficiency disorder. Mol Genet Genomics. 2019;294(2):409–416. doi:10.1007/s00438-018-1517-3
    OpenUrlCrossRef
  29. 29.↵
    Del Bigio MR. Cell proliferation in human ganglionic eminence and suppression after prematurity-associated haemorrhage. Brain. 2011;134(5):1344–1361. doi:10.1093/brain/awr052
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    Shi Y, Wang M, Mi D, et al. Mouse and human share conserved transcriptional programs for interneuron development. Science. 2021;374(6573):eabj6641. doi:10.1126/science.abj6641
    OpenUrlCrossRef
  31. 31.↵
    Lui JH, Hansen DV, Kriegstein AR. Development and Evolution of the Human Neocortex. Cell. 2011;146(1):18–36. doi:10.1016/j.cell.2011.06.030
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    Stuempflen M, Taymourtash A, Kienast P, et al. Ganglionic eminence: volumetric assessment of transient brain structure utilizing fetal magnetic resonance imaging. Ultrasound Obstet Gynecol. 2023;62(3):405–413. doi:10.1002/uog.26232
    OpenUrlCrossRef
  33. 33.↵
    Hansen DV, Lui JH, Flandin P, et al. Non-epithelial stem cells and cortical interneuron production in the human ganglionic eminences. Nat Neurosci. 2013;16(11):1576–1587. doi:10.1038/nn.3541
    OpenUrlCrossRefPubMed
  34. 34.↵
    Prefumo F, Petrilli G, Palumbo G, Sartori E, Izzi C, Pinelli L. Prenatal ultrasound diagnosis of cavitation of ganglionic eminence. Ultrasound Obstet Gynecol. 2019;54(4):558–560. doi:10.1002/uog.20236
    OpenUrlCrossRefPubMed
  35. 35.
    Brusilov M, Malinger G, Erlik U, Haratz KK. Ganglionic eminence cavitations – these are not choroid plexus cysts! Ultrasound Obstet Gynecol. 2021;58(3):483–484. doi:10.1002/uog.23587
    OpenUrlCrossRef
  36. 36.
    Contro E, Volpe N, Larcher L, et al. Normal and abnormal appearance of fetal ganglionic eminence on second-trimester three-dimensional ultrasound. Ultrasound Obstet Gynecol. 2023;62(3):398–404. doi:10.1002/uog.26229
    OpenUrlCrossRef
  37. 37.↵
    Righini A, Frassoni C, Inverardi F, et al. Bilateral Cavitations of Ganglionic Eminence: A Fetal MR Imaging Sign of Halted Brain Development. Am J Neuroradiol. 2013;34(9):1841–1845. doi:10.3174/ajnr.A3508
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    Scarabello M, Righini A, Severino M, et al. Ganglionic Eminence Anomalies and Coexisting Cerebral Developmental Anomalies on Fetal MR Imaging: Multicenter-Based Review of 60 Cases. Am J Neuroradiol. Published online March 11, 2021. doi:10.3174/ajnr.A7062
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    Goergen SK, Alibrahim E, Christie J, et al. The Fetus with Ganglionic Eminence Abnormality: Head Size and Extracranial Sonographic Findings Predict Genetic Diagnoses and Postnatal Outcomes. Am J Neuroradiol. 2021;42(8):1528–1534. doi:10.3174/ajnr.A7131
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    Shwe WH, Schlatterer SD, Williams J, Plessis AJ du, Mulkey SB. Outcome of Agenesis of the Corpus Callosum Diagnosed by Fetal MRI. Pediatr Neurol. 2022;135:44–51. doi:10.1016/j.pediatrneurol.2022.07.007
    OpenUrlCrossRef
  41. 41.↵
    Raile V, Herz NA, Promnitz G, Schneider J, Tietze A, Kaindl AM. Clinical Outcome of Children With Corpus Callosum Agenesis. Pediatr Neurol. 2020;112:47–52. doi:10.1016/j.pediatrneurol.2020.07.013
    OpenUrlCrossRef
  42. 42.↵
    Greenbaum L, Maya I, Sagi-Dain L, et al. Chromosomal Microarray Analysis in Pregnancies With Corpus Callosum or Posterior Fossa Anomalies. Neurol Genet. 2021;7(3):e585. doi:10.1212/NXG.0000000000000585
    OpenUrlAbstract/FREE Full Text
  43. 43.
    D’Antonio F, Pagani G, Familiari A, et al. Outcomes Associated With Isolated Agenesis of the Corpus Callosum: A Meta-analysis. Pediatrics. 2016;138(3):e20160445. doi:10.1542/peds.2016-0445
    OpenUrlCrossRefPubMed
  44. 44.↵
    Rüland AM, Gloning KP, Albig M, et al. The Incidence of Chromosomal Aberrations in Prenatally Diagnosed Isolated Agenesis of the Corpus Callosum. Ultraschall Med - Eur J Ultrasound. 2017;38(06):626–632. doi:10.1055/s-0043-113818
    OpenUrlCrossRef
  45. 45.↵
    Edwards TJ, Sherr EH, Barkovich AJ, Richards LJ. Clinical, genetic and imaging findings identify new causes for corpus callosum development syndromes. Brain. 2014;137(6):1579–1613. doi:10.1093/brain/awt358
    OpenUrlCrossRefPubMed
  46. 46.↵
    Best S, Wou K, Vora N, Van der Veyver IB, Wapner R, Chitty LS. Promises, pitfalls and practicalities of prenatal whole exome sequencing. Prenat Diagn. 2018;38(1):10–19. doi:10.1002/pd.5102
    OpenUrlCrossRefPubMed
Back to top
Posted April 10, 2024.
Download PDF
Email
Characteristic Fetal Brain MRI Abnormalities in Pyruvate Dehydrogenase Complex Deficiency
Olivier Fortin, Kelsey Christoffel, Abdullah Shoaib, Charu Venkatesan, Kate Cilli, Jason W. Schroeder, Cesar Alves, Rebecca D. Ganetzky, Jamie L. Fraser
medRxiv 2024.04.08.24303574; doi: https://doi.org/10.1101/2024.04.08.24303574
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area